Literature DB >> 14507643

Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung.

Hong D Chen1, Armando E Fraire, Isabelle Joris, Raymond M Welsh, Liisa K Selin.   

Abstract

Having previously shown that previous immunity to one virus can influence the host response to a subsequent unrelated virus, we questioned whether the outcome to a given virus infection would be altered in similar or different ways by previous immunity to different viruses, and whether immunity to a given virus would have similar effects on all subsequent infections. In mouse models of respiratory viral infections, immunity to lymphocytic choriomeningitis virus (LCMV), murine cytomegalovirus (MCMV), or influenza A virus enhanced both Th1-type cytokine responses and viral clearance in the lung on vaccinia virus infection. A common pathological feature was the presence of chronic mononuclear infiltrates instead of the acute polymorphonuclear response seen in the infected nonimmune mice, but some pathologies such as enhanced bronchus-associated lymphoid tissue and bronchiolitis obliterans were unique for the immunizing virus, LCMV. Immunity to influenza virus influenced subsequent infections diversely, inhibiting vaccinia virus but enhancing LCMV and MCMV titers and completely altering cytokine profiles. Influenza virus immunity enhanced the mild mononuclear responses usually observed during acute infections with MCMV or LCMV in nonimmune mice, but unique features such as enhanced bronchiolization and mononuclear consolidation occurred during MCMV infection of influenza virus-immune mice. Heterologous immunity induced two patterns of disease outcome dependent on the specific virus infection sequence: improved, if the acute response switched from a neutrophilic to a lymphocytic response or worsened, if it switched from a mild to a severe lymphocytic response. Heterologous immunity thus occurs between many viruses, resulting in altered protective immunity and lung immunopathology, and this is influenced by the specific virus infection sequence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14507643      PMCID: PMC1868309          DOI: 10.1016/S0002-9440(10)63493-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  Memory CD8+ T cells in heterologous antiviral immunity and immunopathology in the lung.

Authors:  H D Chen; A E Fraire; I Joris; M A Brehm; R M Welsh; L K Selin
Journal:  Nat Immunol       Date:  2001-11       Impact factor: 25.606

2.  T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens.

Authors:  Michael A Brehm; Amelia K Pinto; Keith A Daniels; Jonathan P Schneck; Raymond M Welsh; Liisa K Selin
Journal:  Nat Immunol       Date:  2002-06-03       Impact factor: 25.606

Review 3.  Cytomegalovirus pneumonia.

Authors:  N Salomon; D C Perlman
Journal:  Semin Respir Infect       Date:  1999-12

4.  Seroprevalence of lymphocytic choriomeningitis virus in Nova Scotia.

Authors:  T J Marrie; M F Saron
Journal:  Am J Trop Med Hyg       Date:  1998-01       Impact factor: 2.345

Review 5.  Pathology and pathogenesis of arenavirus infections.

Authors:  D H Walker; F A Murphy
Journal:  Curr Top Microbiol Immunol       Date:  1987       Impact factor: 4.291

6.  Rapid recovery of lung histology correlates with clearance of influenza virus by specific CD8+ cytotoxic T cells.

Authors:  C D Mackenzie; P M Taylor; B A Askonas
Journal:  Immunology       Date:  1989-07       Impact factor: 7.397

7.  Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses.

Authors:  L K Selin; S R Nahill; R M Welsh
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

Review 8.  No one is naive: the significance of heterologous T-cell immunity.

Authors:  Raymond M Welsh; Liisa K Selin
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

9.  Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses.

Authors:  R M Welsh; C L O'Donnell; D J Reed; R P Rother
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 10.  Lung transplantation and bronchiolitis obliterans: an evolution in understanding.

Authors:  B W McKane; E P Trulock; G A Patterson; T Mohanakumar
Journal:  Immunol Res       Date:  2001       Impact factor: 4.505

View more
  73 in total

Review 1.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  High intrafamilial variability in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case study.

Authors:  D Capalbo; A Fusco; G Aloj; N Improda; L Vitiello; U Dianzani; C Betterle; M Salerno; C Pignata
Journal:  J Endocrinol Invest       Date:  2011-11-07       Impact factor: 4.256

Review 3.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract.

Authors:  Javier Rangel-Moreno; Damian Carragher; Troy D Randall
Journal:  Inmunologia       Date:  2007

5.  Evaluation of non-reciprocal heterologous immunity between unrelated viruses.

Authors:  Jenny W Che; Liisa K Selin; Raymond M Welsh
Journal:  Virology       Date:  2015-03-31       Impact factor: 3.616

6.  A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes.

Authors:  Urs Christen; Kurt H Edelmann; Dorian B McGavern; Tom Wolfe; Bryan Coon; Meghann K Teague; Stephen D Miller; Michael B A Oldstone; Matthias G von Herrath
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 7.  The impact of successive infections on the lung microenvironment.

Authors:  Arnaud Didierlaurent; John Goulding; Tracy Hussell
Journal:  Immunology       Date:  2007-12       Impact factor: 7.397

Review 8.  The two faces of heterologous immunity: protection or immunopathology.

Authors:  Shalini Sharma; Paul G Thomas
Journal:  J Leukoc Biol       Date:  2013-11-08       Impact factor: 4.962

9.  PC61 (anti-CD25) treatment inhibits influenza A virus-expanded regulatory T cells and severe lung pathology during a subsequent heterologous lymphocytic choriomeningitis virus infection.

Authors:  Anke R M Kraft; Myriam F Wlodarczyk; Laurie L Kenney; Liisa K Selin
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

10.  Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry.

Authors:  Markus Cornberg; Brian S Sheridan; Frances M Saccoccio; Michael A Brehm; Liisa K Selin
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.